Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offering, raising approximately $65 million in initial proceeds.
The offering consisted of pre-funded warrants, Series A warrants, and Series B warrants to purchase shares of common stock or additional pre-funded warrants.
Blockmate Ventures Inc (TSX-V:MATE, OTCQB:MATEF) announced that its investee Hivello has taken significant steps to expand access to its $HVLO token, including entering into a partnership with Banxa to allow its $HVLO token to be purchased directly using fiat currency in over 130 countries.
Hivello’s integration with Banxa allows users to buy $HVLO using common local payment methods such as credit and debit cards, bank transfers, Apple Pay, and Google Pay.
Energy Fuels Inc. (TSX:EFR, NYSE-A:UUUU) shares popped on Tuesday after the uranium producer reported another record month of production at its Pinyon Plain mine in Arizona.
During the month, the company produced nearly 260,000 pounds of uranium oxide (U3O8), representing a 71% increase over last month's record.
Shares of Signet Jewelers Limited (NYSE:SIG) jumped in early trading Tuesday after the world’s largest diamond jewelry retailer posted better-than-expected quarterly earnings and raised its full-year profit forecast, citing resilient consumer demand and strong performance across its store brands.
The company reported adjusted earnings per share of $1.18 for the first quarter of fiscal 2026, beating analyst expectations, as revenue rose 2% to $1.54 billion.
Black Swan Graphene (TSX-V:SWAN) announced that it has ordered a next-generation production unit, increasing its annual graphene production capacity from 40 tonnes to 140 tonnes, positioning it among the leading graphene producers globally.
The new system, the GEA Ariete 3160, is a modular high-pressure homogenizer developed in collaboration with GEA and customized to Black Swan’s proprietary specifications.
First Phosphate Corp. (CSE:PHOS, OTCQB:FRSPF) closed the second and final tranche of a non-brokered private placement, raising a total of C$3.52 million, as the Canadian company advances its development plans.
With this latest financing, First Phosphate has now raised approximately C$23.8 million across seven non-brokered, management-led private placements since June 2022.
GoviEx Uranium Inc (TSX-V:GXU, OTCQB:GVXXF) announced that it has appointed Deogratias Bukunkwe as Project/Commissioning Metallurgist for its Muntanga uranium project in Zambia.
Bukunkwe, a Zambian national, brings over 25 years of experience in process start-up and plant operations, with a particular focus on uranium and heap leach processes.
C3 Metals Inc (TSX-V:CCCM, OTC:CARCF) said it has launched a 14-hole, 2,500-metre diamond drilling program at its 50%-owned Super Block Project in central Jamaica.
The new program is targeting a five-kilometre-long gold trend that includes the past-producing Pennants Gold Mine.
NextSource Materials Inc. (TSX:NEXT, OTCQB:NSRCF) it plans to shift focus to larger-scale development opportunities for its Battery Anode Facility (BAF) project in the Middle East, targeting key sites in Saudi Arabia and the United Arab Emirates.
The Canadian company said the decision follows a prolonged and uncertain regulatory process in Mauritius, which included delays in environmental approvals.
Delivra Health Brands Inc. (TSX-V:DHB) has announced a new partnership with Quality Value Coneience (QVC), a leading US televised and online shopping network specializing in live product demonstrations and direct-to-consumer sales, that aims to expand its presence in the US.
"Once again, our team has been focused on expanding distribution and access points for all types of consumers," Delivra Health CEO Gord Davey said in a statement.
Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF) has updated on the progress of laboratory test work and trade-off studies at its Phalaborwa project in South Africa.
The company’s in-house laboratory in Johannesburg has been operational for around three months.
Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF) has registered its lead clinical trial for a cannabidiol-based medicine on the US government’s trials database, a key step as the company prepares to begin human testing.
The London-based biopharmaceutical company, which is developing pharmaceutical-grade cannabidiol (CBD) treatments for chronic inflammatory pain, said on Tuesday that its phase I study had been posted to ClinicalTrials.gov under reference NCT06854783.